The artificial pancreas device systems (APDS) market has huge opportunities to grow as the existing devices lack efficiency in insulin delivery mechanism. With the advent of enhanced versions of existing devices, which will be closed loop in nature, the market's unmet needs would be addressed during the forecast period.In 2015, Medtronic was leading the market with a share of 58%. It dominates the

market with its established product, MiniMed 530G, which has a unique feature of automatically halting insulin delivery when the glucose level reaches the threshold value. Going forward, the new approvals such as MiniMed 640G in Europe and MiniMed 630G in the US should help it maintain its share in the market.

PART 01: Executive summary 6

Highlights 6

PART 02: Scope of the report 8

Market overview 8

Assumptions 8

Top-vendor offerings 9

PART 03: Market research methodology 10

Research methodology 10

Economic indicators 10

PART 04: Introduction 11

Key market highlights 11

A glance at parent market: Artificial organs 12

PART 05: An overview of pancreas and diabetes 13

Pancreas 13

Diabetes 13

Insulin overview 19

PART 06: Need for better systems in the management of

diabetes 20

PART 07: Artificial pancreas device system 21

Technology landscape 21

PART 08: Initiatives for the development of APDS 25

Juvenile Diabetes Research Foundation (JDRF) initiative

— 2006 25

European Commission’s AP@home project — 2010 25

Centre for bio-inspired technology — Bionic pancreas 26

Harvard University — 2014 26

PART 09: FDA’s role in fostering the development of APDS

27

Rapid response to preliminary study plans 27

Interactive review of investigational device exemption

study plans 27

Guidance and standards for researchers and industry 27

PART 10: Reimbursement scenario 28

Australia 28

Germany 28

UK 29

US 29

PART 11: Key clinical trials 30

PART 12: Market landscape 32

Market overview 32

Five forces analysis 38

PART 13: Market segmentation by categories 39

TSDS 39

NTSDS 40

CTRS 40

CTTS 41

PART 14: Geographical segmentation 45

APDS market in Americas 46

APDS market in EMEA 48

APDS market in APAC 50

PART 15: Market drivers 52

Growing technological integration fuelling the market

growth 52

Increasing initiatives of research organizations fostering

innovation in the market 53

Increasing prevalence of diabetes fuelling the need for

effective devices 54

PART 16: Impact of drivers 56

PART 17: Market challenges 57

Lack of smart control algorithms affecting the adoption

rate of existing APDS 57

Low penetration rates affecting the market growth 57

Lab-grown pancreatic cell transplant as a potential

treatment alternative hindering the growth prospects 58

PART 18: Impact of drivers and challenges 59

PART 19: Market trends 60

Increasing focus on closed loop systems 60

Growing demand for remote monitoring applications 61

Focus of new entrants on the development of novel

APDS 62

PART 20: Vendor landscape 63

Competitive scenario 63

PART 21: Key vendor analysis 69

Medtronic 69

Johnson & Johnson 72

Insulet 74

Tandem Diabetes Care 77

Roche 79

Other prominent vendors 82

PART 22: Appendix 83

List of abbreviations 83

PART 23: Explore Technavio 84